ACD/Labs and Pharma Algorithms join forces
Advanced Chemistry Development (ACD/Labs) and Pharma Algorithms have joined software development and business resources to supply in silico physicochemical, ADME, metabolism, and toxicology screening and prediction solutions.
Both companies feature complementary products of popular computational tools, including molecular property prediction, QSAR modelling, ADME and toxicology prediction, and more.
Until a full integration of products is complete, existing maintenance users of both companies will have access, through their current software package, to the corresponding physicochemical prediction product (including predictions of pKa, logP, logD, and pH-dependent solubility) from the other manufacturer. The current level of integration between ACD/Labs and Pharma Algorithms products offers immediate value to users in computational chemistry departments who can now compare and incorporate a set of models designed using different approaches into their day-to-day work. Further development is expected to produce new products and capabilities aimed at increasing efficiency and cutting project time in drug discovery, metabolism research, and toxicity assessment.
'Our customers will benefit immediately from this merger of technologies and scientific expertise within our two companies,' said Daria Thorp, president of ACD/Labs. 'We look forward to the new innovations that, combined with the existing products from both companies, will create new comprehensive solutions needed by our customers to further their business.'
The entire Pharma Algorithms product line - including modelling software for ADME, toxicology, DMSO solubility, and other products - will be available as part of ACD/Labs' product portfolio exclusively through ACD/Labs' extensive international sales and distribution network.